understanding the requirements for reporting pama private ... · spending for laboratory testing by...
TRANSCRIPT
UnderstandingtheRequirementsforReportingPAMAPrivatePayerLabTestPriceDataEXECUTIVEWARCOLLEGECONFERENCEMAY2,2019
Presentedby
DianaW.Voorhees,M.A.CLS,MT,SH,CPCOPrincipal/CEO
DV&Associates,[email protected]
DV&ASSOCIATES,INC. 2
ObjectivesRelivethecreationofPAMAanditsintenttochangetheClinicalLaboratoryFeeSchedulepaymentmechanismReviewreportingrequirementsandoutcomesthatraisedconcernsfromthelaboratoryindustryDescribefinalrulerequirementsanddiscussparticularlaboratoryconcernsandrelatedCMSresponseDeterminewherewearenowregardingPAMA
DV&ASSOCIATES,INC. 3
BackgroundInformation
ClinicalLaboratoryFeeSchedule(CLFS) Priorto2018:◦ OutpatientclinicallaboratoryserviceswerepaidbasedonafeescheduleinaccordancewithSection1833(h)oftheSocialSecurityAct
◦ Paymentwasthelesseroftheamountbilled,thelocalfeeforageographicarea,oranationallimitation◦ ThenationallimitsweresetatapercentofthemedianofalllocalfeescheduleamountsforeachlaboratoryHCPCScode
◦ Eachyear,feeswereupdatedforinflationbasedonthepercentagechangeintheConsumerPriceIndex
DV&ASSOCIATES,INC. 5
ClinicalLaboratoryFeeSchedule(CLFS)Priorto2018,Cont.◦ LegislationbyCongresscouldmodifytheupdatetothefees◦ Co-paymentsanddeductiblesdonotapplytoservicespaidundertheMedicareclinicallaboratoryfeeschedule
◦ Annually,newlaboratorytestcodeswereaddedtotheclinicallaboratoryfeescheduleandcorrespondingfeesweredevelopedinresponsetoapubliccommentprocess.
DV&ASSOCIATES,INC. 6
CMSConcerns◦ Currentfeeforservicepaymentsmaybeexcessiveespeciallywhencomparedtoprivatepayerpaymentrates◦ Example:50%ofMedicareallowables
◦ Evaluateprivatepayerreimbursements◦ NeededamechanismtooffsetremovaloftheSGR◦ TheCMSoriginalproposalindicatedthat75percentofallcodesintheHealthcareCommonProcedureCodingSystem(HCPCS)wouldrealizepaymentreductionsin2018–firstyearofrevisedfeeschedule.
◦ CMSfurtherestimatedthatthesecutswouldreduceoverallMedicarespendingforlaboratorytestingbynearly11percentor$670millionin2018.
DV&ASSOCIATES,INC. 7
ProtectingAccesstoMedicareAct(PAMA) Section216oftheProtectingAccesstoMedicareAct(PAMA)of2014madeextensivechangestohowreimbursementisdeterminedundertheClinicalLaboratoryFeeSchedule(CLFS).◦ PAMArepealed“technologicalchanges”authoritybyCMStomakeunlimitedreductionstoindividualtestcodeswithoutprovidingclearjustificationorrationale.
◦ Section216createdanewreimbursementframework,basingMedicarepaymentratesforlaboratoryservicespaidundertheCLFSonprivatepayerratesthatarereportedtoCMSby“applicablelaboratories.”
DV&ASSOCIATES,INC. 8
ProtectingAccesstoMedicareAct(PAMA)Basedonthefinalrule,applicablelaboratorieswouldbeginreportingprivatepayerrates,CMSwouldcreateaweightedmedianforeachlaboratoryproceduralcodeontheCLFS,andnewpaymentrateswouldgointoeffectonJanuary1,2017.Scheduleforimplementationwasdelayedayearduetolackofatimelyfinalrule,insufficienttimeforgatheringandreportinginformationbylaboratoriesandinsufficienttimetomassageandanalyzedata
DV&ASSOCIATES,INC. 9
ProtectingAccesstoMedicareAct(PAMA) TheintentofPAMAwastoensuretruemarket-basedpricingbysettingthefeescheduletoaweightedmedianofthecollecteddatafromlaboratories.TheuseofmarketdatatoestablishCLFSpaymentrateswill:◦ StrengthenMedicarebypayingmoreappropriatelyforlaboratoryservices◦ SavetheMedicareprogramandtaxpayersmoney◦ Maintainbeneficiaries’accesstohighqualitylaboratoryservice
DV&ASSOCIATES,INC. 10
ProtectingAccesstoMedicareAct(PAMA) AdditionalOutcome:◦ LocalFeeScheduleseliminated◦ Onlyonerateofreimbursementapplicabletoallgeographicareas
DV&ASSOCIATES,INC. 11
TheBasics
Definitionof“ApplicableLaboratory”◦ Alaboratory,(asdefinedinCMS’sCLIAregulations),usingitsNationalProviderIdentifier(NPI),isconsideredanapplicablelaboratoryifmorethan50percentofitstotalMedicarerevenuesarereceivedfrompaymentsundertheCLFSandphysicianfeeschedule(PFS).
◦ Additionally,anapplicablelaboratorywouldalsohavetoreceiveatleast$12,500inMedicarerevenuesreceivedforCLFSservicesduringadatacollectionperiodtobeanapplicablelaboratory.◦ The$12,500willnotapplytocertainlaboratorieswithrespecttotheADLTstheyofferandfurnish.
DV&ASSOCIATES,INC. 13
AdvanceDiagnosticLaboratoryTest(ADLT) Section216(a)ofPAMAestablishedanewsubcategoryofclinicaldiagnosticlaboratorytests(CLDTs)knownasAdvancedDiagnosticLaboratoryTests(ADLTs)withseparatereportingandpaymentrequirements.◦ CDLTsaredefinedbyCMSasteststhatincludebloodtests,urinalyses,testsontissuespecimens,andsomescreeningandotherteststhatarefurnishedbyapplicablelaboratoriesandcoveredunderMedicarePartB
DV&ASSOCIATES,INC. 14
ADLTDefinition,Cont.◦ PAMAdefinesADLTsasalaboratorytest(CDLT)thatis“coveredunderMedicarePartBthatisofferedandfurnishedonlybyasinglelaboratoryandnotsoldforusebyalaboratoryotherthantheoriginaldevelopinglaboratory(orasuccessorowner)andthatmeetsoneofthefollowingcriteria:◦ Thetestmustmeeteither◦ Criterion(A)(analysisofmultiplebiomarkersofDNA,RNA,orproteins)or◦ Criterion(B)(clearedorapprovedbytheU.S.FoodandDrugAdministration(FDA)).
DV&ASSOCIATES,INC. 15
ADLTDefinition,Cont.◦ OthersimilarcriteriamaybeestablishedbytheSecretaryofHealthandHumanServices◦ Noneexisttodate
◦ Additionally,anADLTtestisananalysisofmultiplebiomarkersofDNA,RNA,orproteinscombinedwithauniquealgorithmtoyieldasinglepatient-specificresult
DV&ASSOCIATES,INC. 16
ADLTExclusion CMSfinalizeditsproposaltoexcludesinglelaboratoriesofferingandfurnishinganADLTfromthe$12,500threshold.◦ ThismeansthatapplicableinformationforanADLTwouldneedtobereported,regardlessofwhetherthelaboratoryfallswithinthelow-expenditurethreshold.
Alaboratorythathaslessthan$12,500inMedicarerevenues,butoffersbothADLTsandCDLTs,muststillreportprivatepayerdatafortheADLT◦ ButprohibitedfromreportingdataonitsCDLTs
DV&ASSOCIATES,INC. 17
ADLTPayment◦ NewADLTswillbepaidatarateequaltotheiractuallistchargeduringanewADLTinitialperiodofthreecalendarquarters.◦ Aftertheinitialperiod,thepaymentamountforanewADLTisbasedontheweightedmedianofprivatepayerratesfromdatacollectedbythelaboratoryduringthenewADLTinitialperiod.
DV&ASSOCIATES,INC. 18
TINversusCLIAversusNPI◦ TIN◦ Frequentlynotassociatedwithjustlaboratorytesting◦ Hospitalsareagoodexample:laboratoryreimbursementwon’tqualifywhencomparedtooverallMedicareincome
◦ CLIA◦ Everylaboratoryhasone◦ MedicalcentermayhaveseveralCLIAnumbersunderoneentity
◦ NPI–winningnumber◦ AllbillingprovidershaveaNPIsomewhere◦ Hospitaloutpatientservicesnowbundled◦ servicesmaybeincludedifmeetthreshold&NPI
DV&ASSOCIATES,INC. 19
Definitionof“ApplicableInformation”◦ ThereportingentitymustreportapplicableinformationforeachCDLTfurnishedbyitscomponentapplicablelaboratories.◦ Applicableinformationistheprivatepayerrateforeachtestforwhichfinalpaymenthasbeenmadeduringthedatacollectionperiod,theassociatedvolumeforeachtest,andthespecificHCPCScodeassociatedwiththetest.◦ Ifanapplicablelaboratoryhasmorethanonepaymentrateforthesameprivatepayerforthesametest,ormorethanonepaymentratefordifferentpayersforthesametest,thereportingentitywillreporteachsuchpaymentrateandthevolumeforthetestateachsuchrate.
DV&ASSOCIATES,INC. 20
Definitionof“ApplicableInformation”Reference:
MedicareLearningNetworkarticleSE1619
“MedicarePartBClinicalLaboratoryFeeSchedule:GuidancetoLaboratoriesforCollectingandReportingDataforthePrivatePayerRate-BasedPaymentSystem”
(1)ThespecificHCPCScodeassociatedwiththetest;
(2)Theprivatepayerrateforeachtestforwhichfinalpayment hasbeenmadeduringthedatacollectionperiod;and(
3)Theassociatedvolumeforeachtest.
DV&ASSOCIATES,INC. 21
InformationNotApplicable◦ TestcodespaidonlyunderthePFS◦ $0.00(denied)payments◦ Unresolvedappeals◦ Capitatedpayments◦ Paymentswheretheassociatedtestvolumecannotbedetermined
DV&ASSOCIATES,INC. 22
FrequencyforReporting Reportingentitiesarerequiredtoreportapplicableinformation:◦ EverythreeyearsforCDLTs◦ EveryyearforADLTs◦ ExceptforanADLTinitsinitialdatacollectionperiod◦ ReportbytheendofthesecondquarterofthenewADLTinitialperiod
◦ Needtoregisterlaboratoryinordertoprocessinformation
DV&ASSOCIATES,INC. 23
PeriodforDataCollection
CMSreviseditsproposeddatacollectionperiodfromafullcalendaryearto6months 2016◦ ThedatacollectionperiodwasJanuary1throughJune30,periodprecedingthenextdatareportingperiod.
◦ CMSfinalizeda6-monthperiodoftimebetweentheendofthedatacollectionperiodandthebeginningofthedatareportingperiodtoprovideanopportunityforlaboratoriesandreportingentitiestoreviewandvalidateapplicableinformationtoensurethedataarecompleteandaccuratebeforeitisreportedtoCMS.
DV&ASSOCIATES,INC. 24
PeriodforDataCollection2017◦ ApplicableinformationwillbereportedforadatacollectionperiodbetweentheJanuary1throughMarch31datareportingperiod.
◦ CMScalculatesrates2018◦ NewratesimplementedJanuary1◦ Nowinnextreportingperiod
DV&ASSOCIATES,INC. 25
DataCertification Certificationofaccuracyandcompletenessofapplicableinformationby:◦ President,CEO,orCFOofanapplicablelaboratory◦ Oradirectreporttowhomtheindividualabovehasdelegatedauthority
DV&ASSOCIATES,INC. 26
Penalties ThestatuteauthorizesCMStoimposecivilmonetarypenaltiesof;◦ CMPupto$10,000perdayfor◦ eachfailuretoreportor◦ eachmisrepresentationoromissioninreportingapplicableinformation.◦ AdjustedforinflationasrequiredbytheInflationAdjustmentActImprovementsActof2015
DV&ASSOCIATES,INC. 27
LimitationsforPaymentReductions PAMAlimitsthereductionofthepaymentamountforanexistingtestascomparedtothepaymentamountfortheprecedingyear.◦ Forthefirstthreeyearsafterimplementation,thestatutelimitsthereductionto10percentperyear◦ 2018-2020
◦ Andto15percentperyearforthefollowingthreeyears.◦ 2021-2023
◦ Thephased-inpaymentamountlimitperyearforexistingtestspaidundertheCLFSpriortoJanuary1,2018willbeappliedusingthe2017nationallimitationamount(NLA)fortheexistingtestasthebaselinepaymentamount.
◦ Todeterminetheapplicationofthephased-inpaymentreductionlimitforatest,theweightedmedianprivatepayerratecalculatedforCY2018willbecomparedtotheCY2017NLA.
DV&ASSOCIATES,INC. 28
SoWhatHappened?
PAMAQuestionableAnalysis AccordingtotheCMS:◦ 90percentofthetestpaymentdatacamefromindependentlaboratories◦ Represent5%ofallUSlaboratories
◦ 9percentcamefromphysicianofficelaboratoriesandhospitals,◦ POLsandhospitalsreportedlyrepresentmorethan43percentofMedicarePartBlabpayments.
◦ Servicesusuallyassociatedwithhigherpaymentlevels◦ 1.85percentofdatawascollectedfromlaboratoriesservingruralareas
DV&ASSOCIATES,INC. 30
PAMAQuestionableAnalysis Ofnote:◦ TheSenateAppropriationsCommitteeforwardedareportwithlanguageregardingtheLabor,HealthandHumanServicesfundingbill◦ UrgedCMStoworkwithstakeholderstoensurethatthenewCLFSratesrepresent"thefullspectrumoflaboratories,includinghospital,independent,andphysicianofficelaboratories"
DV&ASSOCIATES,INC. 31
PAMAQuestionableAnalysis Estimate:◦ Overtenyears,thecutsmaytotalasmuchas$13billion,whichismorethanthreetimestheestimateof$3.9billionCongressoriginallyanticipated
◦ LaboratoryIndustryquestioningadequacyofdatagatheredandthus,theaccuracyoftheanalyticprocesstoreportreliableweightedmediansforindividualproceduralcodes
DV&ASSOCIATES,INC. 32
PAMA–WhatHappened? OnSeptember22,2017,theCentersforMedicareandMedicaidServices(CMS)releaseditsproposednewpaymentratesforlaboratorytestsincludedintheCLFS OnNovember17,2017,CMSpublishedthefinaldeterminationsfor2018CLFSpayments◦ TherewouldbenodelayinusingtheFinaldataweightedmedians◦ CodeswithnoNLAwerecappedata10%reduction
Congressaskedtointercede Suitsanticipated
DV&ASSOCIATES,INC. 33
PAMA&ACLA ThejudgewiththeU.S.DistrictCourtforWashington,DCdismissedACLA’slawsuitthatclaimedtheCLFSchangesunderPAMAwereincorrectlycalculated◦ September21,2018decision◦ Section216ofthePAMAstatuteprohibitsadministrativeorjudicialreviewregardingthesettingofpaymentamounts
◦ Thecourtdoesnothave“subjectmatterjurisdiction”◦ CMS’sdeterminationofpaymentratescannotbechallenged
◦ Additional10%cutsatissueaswellasoriginal2018pricing
DV&ASSOCIATES,INC. 34
ACLAWebsite October19,2018-TheAmericanClinicalLaboratoryAssociation(ACLA)fileditsnoticeofappealinitslawsuitagainsttheU.S.DepartmentofHealthandHumanServices(HHS)challengingitsimplementationoftheProtectingAccesstoMedicareAct(PAMA)◦ “WhiletheDistrictCourtruledonnarrowproceduralgrounds,itsopinionacknowledgesthatACLA’s‘argumentsonthemeritsraiseimportantquestions,’aboutHHS’sactions.WebelieveitiscriticallyimportantforACLAtobeabletoaddresstheseissuesincourt.WhileACLAcontinuestopursuelegalaction,wealsocallonCongresstoreformandmodernizetheClinicalLaboratoryFeeScheduletoensurethatbeneficiariescancontinuetoaccessthelabservicesanddiagnosticstheyneed.”
DV&ASSOCIATES,INC. 35
IndustryResponse ThelaboratorycommunitycalledonCongresstopass"freeze-bridge"legislationtodelaythisnextroundofPAMAcuts.◦ Theproposalwouldfreezethe2018ratesinboth2019and2020allowingtimetodevelopanaccuratemethodologytoimplementPAMA.
◦ Additionally,thesecondroundofdatacollection,scheduledtooccurearlyin2019,wouldalsobedelayeduntilanewmethodologyisinplace.
DV&ASSOCIATES,INC. 36
IndustryResponse Duringthetwo-yearfreezeperiod,CongresswouldrequiretheNationalAcademyofMedicinetoconductastudy◦ Publishrecommendationsonhowtobestimplementtheleastburdensome,statisticallyvaliddatacollectionthatisrepresentativeofthelaboratorymarkets
◦ Establishappropriaterate-settingmethodologythatisrepresentativeofthemarket
◦ Ensuressustainablepatientaccess. ASCLShassetupagrassrootspagetomakeiteasytourgeCongresstotakeaction:www.votervoice.net/ASCLS/campaigns/61741/respond
DV&ASSOCIATES,INC. 37
MPFSFinalRule2018
FinalRule–MPFS November1,2018 CMSannouncedthatitwasincludingMedicareAdvantageProgramservicesinthedefinitionof“applicableLaboratory”underPAMA◦ “..webelievethatmodifyingourdefinitionofapplicablelaboratorysothatwemayreceiveapplicableinformationfrommorelaboratoriesthatfurnishteststoasignificantMedicarePartCpopulation,whicharelesslikelytoqualifyforapplicablelaboratorystatusunderthecurrentpolicy,outweighstheadditionalreportingburdenplacedontheselaboratories”
◦ “..directlysupportsourgoalofcollectingasmuchapplicableinformationaspossiblefromthebroadestrepresentationofthenationallaboratorymarketonwhichtobaseCLFSpaymentamounts”
DV&ASSOCIATES,INC. 39
FinalRule–MPFS CMSannouncedthatitwasincludinghospitaloutreachlaboratoriesinthedefinitionof“applicableLaboratory”underPAMA◦ “..wearefinalizingtherevisionofthedefinitionofapplicablelaboratoryat§414.502toincludeahospitallaboratorythatbillsMedicareontheFormCMS145014xbilltypeanditselectronicequivalent.”
DV&ASSOCIATES,INC. 40
FinalRule–MPFS Impactinquestion◦ MAprograms◦ CMS1450,Billtype14X◦ L1deleted(2016)◦ SeparateNPI◦ IP/OPbundling
DV&ASSOCIATES,INC. 41
NowWhat?
TimeforSecondRoundofReporting 2019◦ ThedatacollectionperiodwillbetheJanuary1throughJune30,periodprecedingthenextdatareportingperiod.
◦ 6-monthperiodoftimetoprovidereviewandvalidateapplicableinformationtoensurethedataarecompleteandaccuratebeforeitisreportedtoCMS.
2020◦ ApplicableinformationwillbereportedbetweenJanuary1andMarch31◦ CMScalculatesrates2021◦ NewratesimplementedJanuary1
DV&ASSOCIATES,INC. 43
GovernmentAccountingOffice(GAO) ArecentNovemberreportrelatedtoPAMAratesforCLFSreimbursementhasraisedanalarmbystatingthat:◦ Maximumpaymentrateswereusedasabaselineratherthanactualpaymentrates◦ NLAcomparisonfor2017payment◦ Projected$733Minincreasedpaymentsin3yr.phase-in
◦ Thepracticeofpayingabundledrateforcertaingroupoftestswaseliminated◦ ATPprocedurecodes◦ ATP02-ATP23◦ Bundledtestsnowhaveseparatepayment◦ Projected$10.3Binincreasedpaymentsin3yrphase-in
DV&ASSOCIATES,INC. 44
SenatorGrassleyCriticismOngoing SenatorCharlesGrassleysensitizedbyreport◦ IowaRepublican◦ ChairofSenateFinanceCommittee◦ SendletterwithquestionstoCMS◦ Believesresponsewasinadequate◦ Requestsraterevision
DV&ASSOCIATES,INC. 45
LaboratoryPush-Back AccusesGAOofmakingflawedanddangerousassertionsbasedonaseriousmisunderstandingofrealworldbillingpractices◦ Projectionsoverblown◦ Laboratorieshavenotchangedbillingpractices
DV&ASSOCIATES,INC. 46
ACLALawsuitAppeal February25◦ TheDepartmentofHealthandHumanServices(HHS)fileditsresponsetoACLA’sappealofitslawsuit
◦ ACLAhasarguedthatHHSimproperlyimplementedtheProtectingAccesstoMedicareActof2014(PAMA)byexcludingprivate-payerdatafromnearlyallhospitaloutreachlabswhenCMSderivednewratesfor2018
◦ HHSdisagreedwithACLA’sstanceandnotedthatthePAMAlawbarsany“administrativeorjudicialreview”tothe“establishmentofpaymentamounts”inthenewprivate-payer-rate-basedCLFS.
DV&ASSOCIATES,INC. 47
ACLALawsuitAppealHHSBriefcontinued:◦ “Inshort,plaintiffseekshigherpaymentamountsthroughanattackontheSecretary’sdefinitionof‘applicablelaboratory.’Howeverframed,thatchallengetothepaymentamountsisbarredbytheplaintextofthestatute,”
◦ OralargumentsfortheappealarescheduledtotakeplaceonApril23,andadecisionbytheU.S.CourtofAppealsfortheDistrictofColumbiaCircuitwillbeissued
DV&ASSOCIATES,INC. 48
HospitalIssues
DiligenceRequired◦ Determineifandwhoare“ApplicableLaboratories”◦ DevelopaPAMAteam◦ Registerwithvendorcollectingdata◦ AssessITsystemsandcapabilities◦ AcquireneededITsoftwareandresources◦ Gainappropriateadviceandtipsforprocess.◦ Collect“applicableinformation”◦ Massagedatatoensureitiscompleteandaccurate◦ Demonstratecompliancewithlaw◦ Reportdatainrequiredformat◦ Staytuned
DV&ASSOCIATES,INC. 50
Discussion
DV&ASSOCIATES,INC. 52
Thankyouforyourcourtesy!
Diana